A randomized trial of the impact of a programmable medication reminder device on quality of life in patients with AIDS

AIDS Patient Care and STDs

Volumn 20, Issue 11, 2006, Pages 773-781

  Wu, Albert W ^a,b,e   Snyder, Claire F ^a,b   Huang, I Chan ^c   Skolasky Jr , Richard ^b   McGruder, Henraya F ^d   Celano, Shivaun A ^b   Selnes, Ola A ^b   Andrade, Adriana S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Health Services Research and Development Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CENTERS FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DEVICE; DISEASE MANAGEMENT ASSISTANCE SYSTEM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSTRUMENTAL ACTIVITIES OF DAILY LIVING; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY HIV HEALTH SURVEY; MEDICATION REMINDER DEVICE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; REMINDER SYSTEMS;

EID: 33845465431     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.773     Document Type: Article

References (26)

1. Haubrich RH, Little SJ, Haubrich RH, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-1107.
2. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937.
3. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
5. Wu AW. Quality of life assessment comes of age in the era of highly active antiretroviral therapy. AIDS 2000;14:1449-1451.
6. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms influence adherence to HAART in persons with HIV infection. J Acquire Immune Defic Syndr 2001;28:445-449.
7. Andrade ASA, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005;41:875-882.
8. Miller EN, Selnes OA, McArthur JC, et al. Neuropsychological performance in HIV-1 infected homosexual men: the Multicenter AIDS Cohort Study (MACS). Neurology 1990;40:197-203.
9. Selnes OA, Jacobson L, Machado AM, et al. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept Mot Skills 1991;73:539-550.
10. Naughton MJ, Shumaker SA, Anderson RT. Psychological aspects of health-related quality of life measurement: tests and scales. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition. Philadelphia: Lippincott-Raven Publishers, 1996:117-113.
11. Naughton MJ, Wiklund IK. Dimension-specific instruments that may be used across cultures. In: Spilker B. ed. Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition. Philadelphia: Lippincott-Raven Publishers, 1996:633-658.
12. Marder K, Albert SM, McDermott MP, et al. Interrater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology 2003;13:60:1467-1473.
13. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: Preliminary validation in persons with early HIV infection. Med Care 1991;29:786-798.
14. Revicki DA, Sorenson S, Wu AW: Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998;36:126-137.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-483.
16. Wu AW, Gray SM, Brookmeyer R. Application of random effects models and other methods to the analysis of multidimensional quality of life data in an AIDS clinical trial. Med Care 1999;37:249-258.
17. Lucas GM, Wu AW, Cheever LW. Adherence to antiretroviral therapy: An update of current concepts. Current HIV/AIDS Rep 2004;1:172-180.
18. Nieuwkerk PT, Gisolf EH, Reijers MH, et al. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001;15:1985-1991.
19. Mannheimer S, Morse E, Matts J, et al. Sustained benefit from a long-term antiretroviral (AR) adherence intervention: Results of a large randomized clinical trial. eJIAS 2004;1:LbOrB15.
20. Andrade A, Davis H, Celano S, et al. Intervention trial using a novel electronic device in HAART initiators: impact of cognitive dysfunction. 8th Conference on Retroviruses and Opportunistic Infections. Chicago: 2001.
21. Kravitz RL, Melnikow J. Medical adherence research. Time for a change in direction? Med Care 2004;42:197-199.
22. Haynes RB, McDonald H, Garg A, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;(2):CD000011.
23. Clotet B, Carmena J, Pulido F, et al. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clin Trials 2004;5:33-39.
24. Penedo FJ, Gonzalez JS, Dahn JR, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res 2003;54:271-278.
25. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: A randomized clinical trial. J Acquire Immune Defic Syndr 2003;34:191-194.
26. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquire Immune Defic Syndr 2002;5:31(Suppl 3):S140-144.